




Figure 3B





2018-08-02 actin short0001




2018-07-30 PC3 cells treated  
short0001

Figure 3B





2018-11-01 RWPE-2 PC3  
U87 stable cells tech1  
SEC23A0001.tif



2018-11-01 RWPE-2 PC3 U87  
stable cells tech1 actin0001.tif

Figure 4C



2018-11-30 PC3 SEC23A  
shRNA Wblot0001



Figure 4C












Figure 4J




200530 Andys CD9 HSPA5 2




210313 Andys


Figure 4J



200529 CD9 HSPA5 4





200529 CD81






Supplementary Figure 1A



2018-05-14 PC3 and U87 EV  
HSPA50001



2018-05-14 PC3 and U87 EV  
CD81 and CK180001